Yashoda Cancer Institute helps Kadapa doctor conquer leukaemia

Dr Rama Devi was diagnosed with a high risk blood cancer known as acute myeloid leukemia (AML) and was successfully treated by Dr. Ganesh Jaishetwar, bone marrow transplant surgeon

By   |  Published: 17th Mar 2021  6:12 pmUpdated: 17th Mar 2021  11:06 pm
Dr Pawan Gorukanti, director, Yashoda Hospitals, and senior oncologists, along with, Dr Rama Devi, senior gynaecologist from Kadapa, who underwent treatment for acute myeloid leukemia.

Hyderabad: Oncologists from Yashoda Cancer Institute, Somajiguda, have successfully treated a senior gynaecologist from Kadapa, Dr Rama Devi, who was diagnosed with leukaemia. Dr Rama Devi was diagnosed with a high risk blood cancer known as acute myeloid leukemia (AML) and was successfully treated by Dr. Ganesh Jaishetwar, bone marrow transplant surgeon.

Due to her medical condition, Dr Rama Devi had lost vision for one eye and had a history of fever and easy bruising over arms and legs. Extensive blood investigations confirmed her diagnosis to be AML.

“With bone marrow transplants, we are successfully curing incurable diseases like leukaemia, myeloma, lymphomas, aplastic anaemia, immunodeficiency disorders, thalassemia etc. and also improving the quality of life for the patients,” Dr. Jaishetwar said.

Dr Rama Devi’s case was quite complex because the cancer had already claimed vision and was hypersensitive to antibiotics and variety of other drugs. With rigorous monitoring and careful management by cancer specialists, she achieved complete control over the complex disease of blood cancer.

Dr. Pawan Gorukanti, Director, Yashoda Hospitals group said “The strength of our Cancer Institute lies in our ability to offer all treatment modalities under one roof. Patients are seen and evaluated in multimodality clinics by a team of specialists in each malignancy”.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .